Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with atrial fibrillation (AF), antiarrhythmic drug therapy currently plays a greater role in maintaining sinus rhythm after cardioversion than it does in converting AF to sinus rhythm. Amiodarone is the most effective antiarrhythmic agent for maintaining sinus rhythm after cardioversion in patients with AF. However, its pharmacokinetics is complex; the drug interacts with many commonly used medications; and long-term use can cause thyroid dysfunction, hepatotoxicity, and other severe extracardiac adverse effects. The use of antiarrhythmic strategies in patients with AF has decreased because of evidence of greater safety and lower costs for hospitalization obtained from the use of rate-control strategies instead. Nevertheless, some patients require a rhythm-control strategy. Warfarin is used to prevent embolic stroke in many patients with AF, but its use is also complex and requires monitoring. Therefore, efforts have been made to develop antiarrhythmic agents with improved tolerability and anticoagulants that are easy to use. OBJECTIVES: To describe the 3 primary goals of pharmacotherapy in patients with AF, compare and contrast the efficacy and safety of established and investigational pharmacotherapies for AF, and recommend a drug regimen for an individual with AF based on patient-specific factors. SUMMARY: Currently available antiarrhythmic agents differ in their efficacy for maintaining sinus rhythm after cardioversion in AF patients with tolerability problems, comorbidities (particularly heart failure and renal impairment), and potential drug interactions. Hence, when selecting drug therapy to maintain sinus rhythm after cardioversion, it is important to take into consideration patient characteristics, including age, disease states, renal function, and concurrent drug therapies. Outpatient self-administration of single loading doses of flecainide or propafenone with what is referred to as the pill-in-the-pocket approach may be considered for carefully selected patients with recurrent episodes of symptomatic AF. The recently approved antiarrhythmic agent dronedarone has electrophysiologic properties similar to those of amiodarone, but its lack of iodine may improve upon the pharmacokinetic and tolerability issues associated with amiodarone. Vernakalant is another investigational antiarrhythmic agent that may prove useful for cardioversion and maintenance of sinus rhythm after cardioversion in patients with AF. New oral anticoagulants that do not require close laboratory monitoring and are simpler to use than warfarin have been used investigationally for prevention of venous thromboembolism and are in clinical trials for prevention of embolic stroke in patients with AF. CONCLUSIONS: Pharmacotherapy for patients with AF should be individualized based on patient-specific factors. New therapeutic options may become available to facilitate treatment of these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Hillestad, R., Bigelow, J., Bower, A., Girosi, F., Meili, R., Scoville, R., & Taylor, R. (2005) · Health Affairs · doi:10.1377/hlthaff.24.5.1103 · Cited by 1,675
Rhythm control versus rate control for atrial fibrillation and heart failure
Roy, D., Talajic, M., Nattel, S., Wyse, D. G., Dorian, P., Lee, K. L., Bourassa, M. G., Arnold, J. M. O., Buxton, A. E., Camm, A. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708789 · Cited by 1,585
Electronic health records in ambulatory care—a national survey of physicians
DesRoches, C. M., Campbell, E. G., Rao, S. R., Donelan, K., Ferris, T. G., Jha, A., Kaushal, R., Levy, D. E., Rosenbaum, S., Shields, A. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0802005 · Cited by 1,111
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826
Walker, J., Pan, E., Johnston, D., Adler-Milstein, J., Bates, D. W., & Middleton, B. (2005) · Health Affairs · doi:10.1377/hlthaff.w5.10 · Cited by 811
Amiodarone versus sotalol for atrial fibrillation
Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041705 · Cited by 749
A cost-benefit analysis of electronic medical records in primary care
Wang, S. J., Middleton, B., Prosser, L. A., Bardon, C. G., Spurr, C. D., Carchidi, P. J., Kittler, A. F., Goldszer, R. C., Fairchild, D. G., Sussman, A. J., et al. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00057-3 · Cited by 740
Costs and benefits of health information technology.
Shekelle, P. G., Morton, S. C., & Keeler, E. B. (2006) · doi:10.23970/ahrqepcerta132 · Cited by 501
Outpatient treatment of recent-onset atrial fibrillation with the “Pill-in-the-Pocket” approach
Alboni, P., Botto, G. L., Baldi, N., Luzi, M., Russo, V., Gianfranchi, L., Marchi, P., Calzolari, M., Solano, A., Baroffio, R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041233 · Cited by 479
Cited by
Mair, F. S., May, C., O’Donnell, C., Finch, T., Sullivan, F., & Murray, E. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.11.099424 · Cited by 553
Castillo, V. H., Martínez-García, A. I., & Pulido, J. (2010) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-10-60 · Cited by 155
Development and formative evaluation of the e-Health Implementation Toolkit (e-HIT)
Murray, E., May, C., & Mair, F. (2010) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-10-61 · Cited by 96
Disparities in Primary Care EHR Adoption Rates
Mack, D., Zhang, S., Douglas, M., Sow, C., Strothers, H., & Rust, G. (2016) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2016.0016 · Cited by 31
Metadata
- Authors
- Kalus, J. S.
- Venue
- Journal of Managed Care Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2009-08
- Volume
- 15
- Issue
- 6 Supp B
- Pages
- 10-18
- ISSN
- 1083-4087 (ISSN-L)
- 1944-706X
- OpenAlex
- W2187741580
- Cited by
- 57
- References
- 13
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options. https://app.cochat.ai/papers/10.18553/jmcp.2009.15.s6-b.10
- The paper
- Kalus, J. S. (2009). Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options. Journal of Managed Care Pharmacy. https://doi.org/10.18553/jmcp.2009.15.s6-b.10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.